Effectiveness of Dapagliflozin for Weight Loss
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.
Also called NCT03968224
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 160 participants
- Sponsor
- Centro Medico Nacional Siglo XXI IMSS
- Registry
-
NCT03968224
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Mexico
- Registry status
- Completed
Technical summary
Registry record NCT03968224. Randomized; no masking; primary purpose treatment. Start 2018-08-04 (actual); primary completion 2024-07-31 (actual). Results posted on 2025-10-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effectiveness of Dapagliflozin for Weight Loss
- Condition
- PreDiabetes
- Condition
- Obesity, Morbid
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Dapagliflozin/Metformin
- Intervention (Drug)
- Metformin
- Lead sponsor
- Centro Medico Nacional Siglo XXI IMSS
Record details
- Record id
cardio:ct-nct03968224- Content hash
b26c9255fe335ea01fdfa9eb802c28bb571be91a271d39f0062c4b7c8302742a